Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses (Q45415101)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 June 2006

Language	Label	Description	Also known as
English	Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses	scientific article published on 6 June 2006

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses (English)

1 reference

Europe PubMed Central

14 December 2017

Alzheimer's disease

0 references

1 reference

based on heuristic

inferred from title

Bryce Chackerian

1

object named as

Bryce Chackerian

1 reference

Europe PubMed Central

14 December 2017

author name string

Marisa Rangel

2

1 reference

Europe PubMed Central

14 December 2017

Zoe Hunter

3

1 reference

Europe PubMed Central

14 December 2017

David S Peabody

4

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

6 June 2006

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

24

1 reference

Europe PubMed Central

14 December 2017

6321-6331

1 reference

Europe PubMed Central

14 December 2017

37-39

1 reference

Europe PubMed Central

14 December 2017

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Maturation of papillomavirus capsids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Efficient intracellular assembly of papillomaviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Humoral Immune Response to Fibrillar β-Amyloid Peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Determinants of autoantibody induction by conjugated papillomavirus virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

The crystal structure of bacteriophage Q beta at 3.5 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

The refined structure of bacteriophage MS2 at 2.8 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Crystal structure of the MS2 coat protein dimer: implications for RNA binding and virus assembly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Immunotherapeutic Approaches to Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Immunogenicity of engineered antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.059

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.05.059

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45415101&oldid=2076863085"